Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients
- 27 June 1980
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 243 (24) , 2513-2515
- https://doi.org/10.1001/jama.243.24.2513
Abstract
In 5 hyponatremic, cirrhotic patients, demeclocycline hydrochloride was used to inhibit the hydroosmotic effect of vasopressin. In 4, renal impairment developed during the 7-20 days of demeclocycline hydrochloride (900-1200 mg/day) administration. In these 4 patients, creatinine clearance fell (72-20 ml/min, P < .01) as blood urea N (12-47 mg/dl, P < .02) and serum creatinine (0.9-4.2 mg/dl, P < .01) levels rose. The azotemic effect of the drug could not be accounted for consistently by volume depletion secondary to its natriuretic effect. A close correlation between plasma demeclocycline levels and its azotemic effect was observed. A nephrotoxic effect of demeclocycline severely limits its usefulness in treating hyponatremia in the cirrhotic patient.This publication has 5 references indexed in Scilit:
- Renal Failure Associated with Demeclocycline in CirrhosisAnnals of Internal Medicine, 1977
- Demeclocycline and Therapy of HyponatremiaAnnals of Internal Medicine, 1977
- Demeclocycline Treatment of Water Retention in CirrhosisAnnals of Internal Medicine, 1976
- Demeclocycline-Induced Nephrogenic Diabetes InsipidusAnnals of Internal Medicine, 1973
- Renal Disease and the Metabolic Effects of TetracyclineAnnals of Internal Medicine, 1963